NeuroneticsFRA:NRC -5.13%51 Days Payable is 54.94 as of Mar. 2026, which is 37% below its 10-year median of 86.83. GuruFocus rates FRA:NRC with a GF Score™ of 51/100 and a GF Value™ of €1.52 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Neuronetics ranks worse than 67.8% on this metric.
The historical rank and industry rank for Neuronetics's Days Payable or its related term are showing as below:
FRA:NRC'
s Days Payable Range Over the Past 10 Years
Min: 48.06 Med: 86.83 Max: 139.36
Current: 48.06
During the past 10 years, Neuronetics's highest Days Payable was 139.36. The lowest was 48.06. And the median was 86.83.
FRA:NRC's Days Payable is ranked worse than 67.8% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs FRA:NRC: 48.06
Neuronetics's Days Payable
declined
from Mar. 2025 (55.97) to Mar. 2026 (54.94).
It may suggest that Neuroneticsaccelerated paying its suppliers.
Neuronetics Days Payable Related Terms
Neuronetics Days Payable Historical Data
* Premium members only.
The historical data trend for Neuronetics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NRC vs ZOMDF, OM, RPID: Days Payable Comparison
For the Medical Devices subindustry, Neuronetics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuronetics Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Neuronetics's Days Payable distribution charts can be found below:
* The bar in red indicates where Neuronetics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Neuronetics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuronetics (FRA:NRC) has a Days Payable of 54.94 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Neuronetics and its competitors. This is 37% below median its historical median of 86.83. Over the past decade, Neuronetics' Days Payable has ranged from 48.06 to 139.36. According to the industry distribution chart, Neuronetics ranks #539 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 67.8%.
Is Neuronetics' Days Payable too high?
Neuronetics' current Days Payable of 54.94 is 37% below median its 10-year median of 86.83. Over the past 10 years, this metric has ranged from a low of 48.06 to a high of 139.36. The Medical Devices & Instruments industry median Days Payable is 68.07. Neuronetics' value of 54.94 is 19.3% below this industry median. Based on the distribution chart, Neuronetics ranks #539 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Neuronetics has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neuronetics' Days Payable compare to ZOMDF and OM?
According to the Medical Devices & Instruments industry distribution chart, Neuronetics ranks #539 out of 795 companies for Days Payable. This places Neuronetics in the lower half of its industry. The industry median Days Payable is 68.07. Neuronetics' value of 54.94 is 19.3% below this benchmark. Historically, Neuronetics' own Days Payable has ranged from 48.06 to 139.36 over the past decade. While the company's 10-year median is 86.83 vs. the industry median of 68.07, Neuronetics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuronetics's current Days Payable of 54.94 is 19.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Neuronetics and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuronetics's current Days Payable is 54.94, which is 37% below median its own 10-year median of 86.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuronetics stock overvalued right now?
Based on GuruFocus' analysis, Neuronetics (FRA:NRC) is currently considered Modestly Undervalued. The stock's GF Value™ is €1.52, compared to a current price of €1.11 — trading 27% below its estimated fair value. The current Days Payable is 54.94, which is 37% below median its 10-year median of 86.83 and 19.3% below the Medical Devices & Instruments industry median of 68.07. Neuronetics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Neuronetics (FRA:NRC), the current Days Payable is 54.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuronetics (FRA:NRC) Overvalued in 2026?
Based on GuruFocus' analysis, Neuronetics stock appears to be undervalued.
The current stock price of €1.11 is trading 27% below its estimated GF Value™ of €1.52.
GuruFocus considers Neuronetics to be Modestly Undervalued.
Key valuation signals for FRA:NRC:
Days Payable: 54.94 (37% below median its 10-year median of 86.83)
GF Value™: €1.52 vs. price of €1.11 (27% below fair value)
Industry Position: 19.3% below the Medical Devices & Instruments median (#539 of 795)
No single metric tells the full story. See the FRA:NRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
51GF Score
Get the complete analysis for FRA:NRC
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NRC has been successfully added to your 
